Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | April 13, 2022 | April 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date April 13, 2022 · Filed April 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.11 · Expires 2032-04-13 | Direct | 33,000 |
Reported balance
After 2022-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-13 · Grant · Acquired 33,000 · Balance 33,000 F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CRH Medical Corp
Report date April 22, 2021 · Filed April 27, 2021
Section 16 reporting ended · disclosed 2021-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-04-22 · Disposition to issuer · Disposed 495,313 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2023-12-12 | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-22 · Disposition to issuer · Disposed 4,687 · Balance 0 F2: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-22 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Each CRH RSU represented a contingent right to receive one CRH share. F2: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. F4: The Restricted Share Units expire on the earlier of June 30, 2021 or one day prior to the next Annual General Meeting of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held.
F2: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs.
F3: Each CRH RSU represented a contingent right to receive one CRH share.
F4: The Restricted Share Units expire on the earlier of June 30, 2021 or one day prior to the next Annual General Meeting of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2022 Filed Apr 15, 2022 19:55 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046455 · tm2212851-8_4seq1.xml · derivative · entry 1 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 20:03 UTC | CRH Medical Corp CRHM · Entity 139998 | Disposition to issuerRestricted Share Units · Derivative | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001209191-21-028733 · doc4.xml · derivative · entry 3 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each CRH RSU represented a contingent right to receive one CRH share. F2 · derivative.exercise_date: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. F4 · derivative.expiration_date: The Restricted Share Units expire on the earlier of June 30, 2021 or one day prior to the next Annual General Meeting of the Issuer. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 20:03 UTC | CRH Medical Corp CRHM · Entity 139998 | Disposition to issuerStock Options (Right to Buy) · Derivative | 4,687 | $3.52 Strike: $0.48 | $16,498.24 |
DisclosureSEC source: 0001209191-21-028733 · doc4.xml · derivative · entry 2 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,687 shares Expires 2023-12-12 F2 · derivative.exercise_date: All options to acquire CRH shares ("CRH options") and share units with respect to CRH shares ("CRH RSUs") outstanding immediately prior to the Effective Time were exchanged for either a cash payment equal to Share Consideration (less the applicable exercise price in respect of CRH options) or replacement options or restricted stock units with respect to WELL common shares, in accordance with the terms of the Arrangement Agreement and the plan of arrangement subject to the same vesting schedule as applied to the CRH RSUs. Read SEC document |
| April 22, 2021 Filed Apr 27, 2021 20:03 UTC | CRH Medical Corp CRHM · Entity 139998 | Disposition to issuerCommon Shares | 495,313 | $4.00 | $1,981,252.00 |
DisclosureSEC source: 0001209191-21-028733 · doc4.xml · nonDerivative · entry 1 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Pursuant to the Arrangement Agreement, dated as of February 6, 2021 (as amended, the "Arrangement Agreement"), by and among CRH Medical Corporation ("CRH"), WELL Health Technologies Corp. ("WELL"), WELL Health Acquisition Corp., a wholly owned subsidiary of WELL, and 1286392 B.C. Ltd, a wholly owned subsidiary of WELL, at 4:30 p.m. Eastern Time (the "Effective Time") on April 22, 2021 each common share of CRH (each, a "CRH share") issued and outstanding immediately before the Effective Time was transferred to a subsidiary of WELL, and the holders thereof became entitled to receive US$4.00 in cash, without interest and less any applicable withholding taxes (the "Share Consideration"), for each CRH share then held. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 23:35 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001104659-21-042630 · tm2111079-3_4seq1.xml · derivative · entry 1 Patrick Todd · CIK 0001762285 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2031-03-25 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each of the first, second, third and fourth annual anniversaries of the date of grant. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:11 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-20-133644 · tm2038059-11_4seq1.xml · derivative · entry 1 Patrick Todd · CIK 0001762285 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:10 UTC | CRH Medical Corp CRHM · Entity 139998 | GrantRestricted Share Unit · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036822 · doc4.xml · derivative · entry 1 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F2 · derivative.exercise_date: Restricted Share Units vest on or before expiration date. F3 · derivative.expiration_date: The Restricted Share Units will expire on the earlier of June 30, 2021 or one day prior to the next Annual General Meeting of the Issuer. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:47 UTC | CRH Medical Corp CRHM · Entity 139998 | GrantCommon Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037322 · doc4.xml · nonDerivative · entry 2 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,313 F2 · shares: Represents 20,000 Common Shares to be issued upon settlement of 20,000 Restricted Share Units granted on June 13, 2019. The Restricted Share Units will expire on the earlier of June 30, 2020 or one day prior to the next Annual General Meeting of the Issuer. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:47 UTC | CRH Medical Corp CRHM · Entity 139998 | Exercise / conversionRestricted Share Units · Derivative | 16,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037322 · doc4.xml · derivative · entry 3 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,000 shares Expires 2019-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. F3 · derivative.exercise_date: Restricted Share Units vest on or before expiration date. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:47 UTC | CRH Medical Corp CRHM · Entity 139998 | Exercise / conversionCommon Shares | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037322 · doc4.xml · nonDerivative · entry 1 Patrick Todd · CIK 0001762285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit represents the right to receive one Common Share upon settlement. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 298,724 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028259 · tv522365_4.xml · derivative · entry 1 Patrick Todd · CIK 0001762285 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,724 Underlying: Common Stock · 298,724 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to twenty-five percent (25%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.